In a recent study, more than 40% of patients with relapsed or refractory germ cell tumors experienced a clinical benefit with cabozantinib.

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...

Cornell researchers have confirmed that a previously identified biomarker for detecting the presence of malignant testicular germ cell tumors—the most common solid cancers in young men—has the ...

Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...

Can fragments of tumor DNA in the blood predict whether chemotherapy will be effective? Researchers at the Princess Máxima Center investigated this question together with experts from Italy and ...

Although pediatric cancer is rare, it is the leading cause of death by disease in children, according to the National Institutes of Health (NIH). Over 16,000 children in the United States are ...

Testicular germ cell tumors are on the rise in the US. The incidence among Hispanic men now surpasses that of non-Hispanic White men, who have historically had the highest incidence. The incidence of ...

A study conducted by the Molecular Oncology Research Center (CPOM) at Hospital de Amor in Barretos (formerly Barretos Cancer Hospital) in the state of São Paulo, Brazil, has identified possible ...

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial TF was detectable in 75.4% ...

Impact of urinary tract infections on in-hospital outcomes among prostate cancer patients: An NIS-based analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...